July - 20216July - 05 - 2021, volume 04 - Issue 26 (ISSN 2691-4093)Published by ValleyMedia, Inc. Managing EditorAlex D'souzaEditorial StaffVisualizerJohn GothamSalesAndrew D'Souzaandrew.dsouza@medicaltechoutlook.com510.996.5123Contact usEmailPhone:510 230 0396 Fax:510-894-8405sales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comJoshua Parker Merlin WatsonJoe Philip Laura PintoTo subscribe to MedicalTech OutlookVisit www.medicaltechoutlook.com Copyright © 2021 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffAlex D'souzaManaging Editoreditor@medicaltechoutlook.comThe traditional paradigm of the pharmaceutical field is changing rapidly. The breakneck speed of vaccine development that we already observed in 2020 is continuing well into 2021. Today, while the public-private initiative, Operation Warp Speed, is winning public attention for speeding up vaccine development and distribution, it is also drawing attention to common bottlenecks of clinical trial processes. And subsequently, it is paving the way for drug development and delivery regulations to also make necessary alterations. This can be observed in terms of revised dosage forms and noble multifunctional drug delivery systems (both micro and nanoparticulate). The changing landscape is also forcing drug developers to rethink how to manage clinical trials and treat patients in hospitals and at homes as well. Drug developers are now looking at steps the life sciences industry could take to reduce those tailbacks and speed up the process for other drug candidates.In this edition of MedTech Outlook, we bring you the story of EsoCap--one of the most promising drug delivery devices solution providers in Europe. The company has developed an ingenious drug delivery platform to deliver drugs for eosinophilic esophagitis (EoE). This edition also offers a combination of thought leadership articles from subject matter experts and exclusive insights from CIOs and CXOs. We hope this edition will provide you with the right assistance in choosing the best drug delivery devices solution providers according to your requirements.Let us know your thoughts!Ushering in the Era of Multifunctional Drug Delivery SystemsSarah FernandesEDITORIAL
< Page 5 | Page 7 >